New data on Lilly's investigational treatment olomorasib at ESMO 2026 show durable first-line activity in KRAS G12C-mutant non-small cell lung cancer

At ESMO, Lilly reported investigational olomorasib plus chemoimmunotherapy produced a 62% confirmed response rate and 14.5-month median duration of response among 77 first-line patients with advanced KRAS G12C-mutant NSCLC; median progression-free survival was 11.6 months. In a separate 85-patient analysis of olomorasib plus pembrolizumab without chemotherapy, median response duration and progression-free survival had not been reached after 20.7 months’ median follow-up; Grade 3 or higher treatment-related adverse events included elevated ALT (15.3%), elevated AST (12.9%) and diarrhea (8.2%), with no Grade 5 events. Olomorasib is not approved, and Lilly expects first randomized Phase 3 data from SUNRAY-01 in the first half of 2027.

Analysis

The investable signal is pipeline de-risking, not a near-term earnings revision for Lilly: the efficacy comes from small, non-randomized cohorts, and the pivotal randomized readout—not cross-trial comparison—is the value inflection. “Not reached” PFS/DOR in the pembrolizumab cohort is encouraging but vulnerable to immature follow-up and patient selection; dose reductions and liver-enzyme toxicity are meaningful counterweights to the tolerability positioning. A positive Phase 3 could establish a first-line targeted-combination franchise in a setting where many patients never reach later-line treatment, expanding the addressable treatment opportunity rather than merely shifting use between lines. Conversely, it could pressure later-line KRAS G12C inhibitor demand, including Amgen’s and Bristol Myers Squibb’s offerings, if treatment moves forward. Merck’s pembrolizumab is already part of standard-of-care regimens and the trial comparator, so incremental Keytruda usage is not established; this is not a distinct MRK catalyst. Near term, expect limited fundamental impact versus Lilly’s scale. The 1–3 month path is trial execution and subsequent data detail; the key catalyst is the randomized Part B readout expected in 1H 2027. Over 6–18 months, success depends on clinically meaningful benefit versus chemoimmunotherapy and manageable combination toxicity. The contrarian point: optimistic company framing may underweight the gap between single-arm activity and randomized benefit, while investors may also underappreciate the commercial value of moving targeted therapy into the first line if confirmed. Failure to show a meaningful PFS benefit, excess discontinuations/hepatotoxicity, or a delayed readout would undermine the thesis.

Key Decisions for Investors

• Treat the ESMO update as modestly positive pipeline optionality for LLY, not a basis for a material near-term earnings or valuation upgrade; avoid chasing a headline-driven move without randomized evidence.
• Keep LLY on a catalyst watchlist into the SUNRAY-01 Part B readout expected in 1H 2027. Verify the randomized PFS effect, confidence intervals, overall-survival follow-up, and discontinuation/liver-toxicity rates before sizing a directional position.
• No standalone MRK trade: pembrolizumab is embedded in both standard care and the study design, and the release does not establish incremental Keytruda sales.
• Monitor first-line KRAS G12C trial results from competing programs and later-line inhibitor demand. A durable first-line benefit could shift treatment value earlier; weak randomized results would leave established chemoimmunotherapy and later-line options largely intact.